| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Frontier Science Research Center, Kagoshima University, Kagoshima 890-8544, Japan,1 Division of Antiviral Chemotherapy, Center for Chronic Viral Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8544, Japan,2 Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium3
Received 13 February 2007/ Returned for modification 29 March 2007/ Accepted 24 April 2007
Several anti-human immunodeficiency virus type 1 reverse transcriptase inhibitors were evaluated for their antiviral activities against porcine endogenous retrovirus in human cells. Among the test compounds, zidovudine was found to be the most active. The order of potency was zidovudine > phosphonylmethoxyethoxydiaminopyrimidine = phosphonylmethoxypropyldiaminopurine > tenofovir
adefovir > stavudine.
Published ahead of print on 30 April 2007.
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |